View ValuationIntegraGen 将来の成長Future 基準チェック /06現在、 IntegraGenの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長58.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Jul 02IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025IntegraGen SA omits to maintain revenue guidance for the full year of 2025. For the period, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the company is not maintaining its revenue growth forecasts for 2025.Breakeven Date Change • Jun 20Forecast to breakeven in 2021The analyst covering IntegraGen expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2021. Earnings growth of 122% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • May 14IntegraGen SA, Annual General Meeting, May 13, 2026IntegraGen SA, Annual General Meeting, May 13, 2026. Location: evry FranceNew Risk • Apr 28New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€909k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€909k). Earnings have declined by 51% per year over the past 5 years. Market cap is less than US$10m (€1.12m market cap, or US$1.31m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-€1.6m).New Risk • Nov 03New major risk - Revenue and earnings growthEarnings have declined by 30% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (€999.7k market cap, or US$1.15m).分析記事 • Oct 03IntegraGen SA (EPA:ALINT) Looks Inexpensive After Falling 41% But Perhaps Not Attractive EnoughThe IntegraGen SA ( EPA:ALINT ) share price has fared very poorly over the last month, falling by a substantial 41...Board Change • Oct 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Francois Fontaine was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 02IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025IntegraGen SA omits to maintain revenue guidance for the full year of 2025. For the period, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the company is not maintaining its revenue growth forecasts for 2025.お知らせ • May 16IntegraGen SA, Annual General Meeting, Jun 19, 2025IntegraGen SA, Annual General Meeting, Jun 19, 2025. Location: genopole campus 1 genavenir 8, 5 rue henri desbrueres, evry FranceNew Risk • May 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€4.14m market cap, or US$4.71m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.8% average weekly change).New Risk • Feb 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (€3.58m market cap, or US$3.75m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).分析記事 • Dec 14Why Investors Shouldn't Be Surprised By IntegraGen SA's (EPA:ALINT) Low P/SWith a price-to-sales (or "P/S") ratio of 0.3x IntegraGen SA ( EPA:ALINT ) may be sending very bullish signals at the...New Risk • Nov 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (€3.11m market cap, or US$3.27m). Minor Risk Latest financial reports are more than 6 months old (reported December 2023 fiscal period end).New Risk • Sep 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$10m (€3.44m market cap, or US$3.79m).分析記事 • Aug 28Lacklustre Performance Is Driving IntegraGen SA's (EPA:ALINT) Low P/SWith a price-to-sales (or "P/S") ratio of 0.3x IntegraGen SA ( EPA:ALINT ) may be sending very bullish signals at the...お知らせ • May 17IntegraGen SA, Annual General Meeting, Jun 20, 2024IntegraGen SA, Annual General Meeting, Jun 20, 2024. Location: genopole campus 1 genavenir 8, 5 rue henri desbrueres, evry FranceReported Earnings • May 06Full year 2023 earnings releasedFull year 2023 results: Revenue: €12.8m (down 2.9% from FY 2022). Net loss: €171.4k (loss widened €167.9k from FY 2022).分析記事 • Feb 17There's No Escaping IntegraGen SA's (EPA:ALINT) Muted RevenuesWith a price-to-sales (or "P/S") ratio of 0.5x IntegraGen SA ( EPA:ALINT ) may be sending very bullish signals at the...お知らせ • Jan 17IntegraGen SA to Report Fiscal Year 2023 Results on Apr 24, 2024IntegraGen SA announced that they will report fiscal year 2023 results on Apr 24, 2024New Risk • Oct 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€6.32m market cap, or US$6.69m). Minor Risk Share price has been volatile over the past 3 months (6.2% average weekly change).分析記事 • Apr 19Pinning Down IntegraGen SA's (EPA:ALINT) P/E Is Difficult Right NowWhen close to half the companies in France have price-to-earnings ratios (or "P/E's") below 15x, you may consider...お知らせ • Jan 11+ 1 more updateIntegraGen SA to Report Fiscal Year 2022 Results on Apr 24, 2023IntegraGen SA announced that they will report fiscal year 2022 results on Apr 24, 2023Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.43, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 12x in the Biotechs industry in France. Total returns to shareholders of 33% over the past three years.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 20First half 2022 earnings releasedFirst half 2022 results: Revenue: €6.76m (up 34% from 1H 2021). Net loss: €141.0k (loss narrowed 66% from 1H 2021).Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 10First half 2021 earnings releasedThe company reported a soft first half result with weaker earnings and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €5.14m (up 9.2% from 1H 2020). Net loss: €411.0k (down €427.6k from profit in 1H 2020).Breakeven Date Change • Jun 20Forecast to breakeven in 2021The analyst covering IntegraGen expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2021. Earnings growth of 122% is required to achieve expected profit on schedule.Reported Earnings • Apr 26Full year 2020 earnings releasedThe company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €9.15m (up 11% from FY 2019). Net loss: €375.0k (loss widened 32% from FY 2019).Is New 90 Day High Low • Nov 16New 90-day low: €2.12The company is down 3.0% from its price of €2.18 on 18 August 2020. The French market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period.Is New 90 Day High Low • Oct 24New 90-day high: €2.30The company is up 5.0% from its price of €2.20 on 24 July 2020. The French market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 13% over the same period.お知らせ • Sep 17OncoDNA SA signed an agreement to acquire IntegraGen SA (ENXTPA:ALINT) for €14.5 million.OncoDNA SA signed an agreement to acquire IntegraGen SA (ENXTPA:ALINT) for €14.5 million on July 8, 2020. OncoDNA will acquire all shares of IntegraGen at an offer per share of €2.20. The transaction is structured as a tender offer. The transaction is subject to the approval of the Autorité des Marchés Financiers and applicable regulations to foreign investment control in France. The offer was approved on a unanimous basis by all members of the Board of both companies. As of September 15, 2020, the transaction was approved by AMF. The offer shall be opened at the end of the third quarter of 2020. On September 16, 2020, Oncodna formally launched the tender offer and will be open for acceptances in the next 25 days. ODDO BHF SCA acted as financial advisor, White & Case LLP Avocats-Advocaten and Osborne Clarke BV CVBA acted as legal advisors for OncoDNA. Portzamparc acted as financial advisor, Olivier Grivillers of Crowe HAF acted as fairness opinion provider and Jones Day acted as legal advisor for IntegraGen. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、IntegraGen は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ENXTPA:ALINT - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20255-3-2-2N/A9/30/20256-2N/AN/AN/A6/30/20257-2N/AN/AN/A3/31/20258-1N/AN/AN/A12/31/202490N/AN/AN/A9/30/2024100N/AN/AN/A6/30/2024110N/AN/AN/A3/31/2024120N/AN/AN/A12/31/2023130N/AN/AN/A9/30/2023130N/AN/AN/A6/30/2023130N/AN/AN/A3/31/2023130N/AN/AN/A12/31/2022130N/AN/AN/A9/30/2022130N/AN/AN/A6/30/2022130N/AN/AN/A3/31/2022120N/AN/AN/A12/31/2021110N/AN/AN/A9/30/2021100N/AN/AN/A6/30/20219-1N/AN/AN/A3/31/20219-1N/AN/AN/A12/31/202090N/AN/AN/A9/30/202090N/AN/AN/A6/30/202090N/AN/AN/A3/31/202090N/AN/AN/A12/31/201980N/AN/AN/A9/30/20198-1N/AN/AN/A6/30/20197-1N/AN/AN/A3/31/20197-1N/AN/AN/A12/31/20187-1N/AN/AN/A9/30/20187-1N/AN/AN/A6/30/20187-1N/AN/AN/A3/31/20187-1N/AN/AN/A12/31/20177-1N/AN/AN/A9/30/20176-1N/AN/AN/A6/30/20177-1N/AN/AN/A3/31/20176-1N/AN/AN/A12/31/20166-2N/AN/AN/A9/30/20166-2N/AN/AN/A6/30/20166-2N/AN/AN/A3/31/20166-2N/AN/AN/A12/31/20156-2N/AN/AN/A9/30/20156-1N/AN/AN/A6/30/20156-1N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ALINTの予測収益成長が 貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ALINTの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ALINTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ALINTの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ALINTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ALINTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/26 06:53終値2026/06/26 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋IntegraGen SA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Arnaud GuérinPortzamparc BNP Paribas
お知らせ • Jul 02IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025IntegraGen SA omits to maintain revenue guidance for the full year of 2025. For the period, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the company is not maintaining its revenue growth forecasts for 2025.
Breakeven Date Change • Jun 20Forecast to breakeven in 2021The analyst covering IntegraGen expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2021. Earnings growth of 122% is required to achieve expected profit on schedule.
お知らせ • May 14IntegraGen SA, Annual General Meeting, May 13, 2026IntegraGen SA, Annual General Meeting, May 13, 2026. Location: evry France
New Risk • Apr 28New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€909k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€909k). Earnings have declined by 51% per year over the past 5 years. Market cap is less than US$10m (€1.12m market cap, or US$1.31m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-€1.6m).
New Risk • Nov 03New major risk - Revenue and earnings growthEarnings have declined by 30% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (€999.7k market cap, or US$1.15m).
分析記事 • Oct 03IntegraGen SA (EPA:ALINT) Looks Inexpensive After Falling 41% But Perhaps Not Attractive EnoughThe IntegraGen SA ( EPA:ALINT ) share price has fared very poorly over the last month, falling by a substantial 41...
Board Change • Oct 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Francois Fontaine was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 02IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025IntegraGen SA omits to maintain revenue guidance for the full year of 2025. For the period, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the company is not maintaining its revenue growth forecasts for 2025.
お知らせ • May 16IntegraGen SA, Annual General Meeting, Jun 19, 2025IntegraGen SA, Annual General Meeting, Jun 19, 2025. Location: genopole campus 1 genavenir 8, 5 rue henri desbrueres, evry France
New Risk • May 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€4.14m market cap, or US$4.71m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.8% average weekly change).
New Risk • Feb 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (€3.58m market cap, or US$3.75m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
分析記事 • Dec 14Why Investors Shouldn't Be Surprised By IntegraGen SA's (EPA:ALINT) Low P/SWith a price-to-sales (or "P/S") ratio of 0.3x IntegraGen SA ( EPA:ALINT ) may be sending very bullish signals at the...
New Risk • Nov 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (€3.11m market cap, or US$3.27m). Minor Risk Latest financial reports are more than 6 months old (reported December 2023 fiscal period end).
New Risk • Sep 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$10m (€3.44m market cap, or US$3.79m).
分析記事 • Aug 28Lacklustre Performance Is Driving IntegraGen SA's (EPA:ALINT) Low P/SWith a price-to-sales (or "P/S") ratio of 0.3x IntegraGen SA ( EPA:ALINT ) may be sending very bullish signals at the...
お知らせ • May 17IntegraGen SA, Annual General Meeting, Jun 20, 2024IntegraGen SA, Annual General Meeting, Jun 20, 2024. Location: genopole campus 1 genavenir 8, 5 rue henri desbrueres, evry France
Reported Earnings • May 06Full year 2023 earnings releasedFull year 2023 results: Revenue: €12.8m (down 2.9% from FY 2022). Net loss: €171.4k (loss widened €167.9k from FY 2022).
分析記事 • Feb 17There's No Escaping IntegraGen SA's (EPA:ALINT) Muted RevenuesWith a price-to-sales (or "P/S") ratio of 0.5x IntegraGen SA ( EPA:ALINT ) may be sending very bullish signals at the...
お知らせ • Jan 17IntegraGen SA to Report Fiscal Year 2023 Results on Apr 24, 2024IntegraGen SA announced that they will report fiscal year 2023 results on Apr 24, 2024
New Risk • Oct 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€6.32m market cap, or US$6.69m). Minor Risk Share price has been volatile over the past 3 months (6.2% average weekly change).
分析記事 • Apr 19Pinning Down IntegraGen SA's (EPA:ALINT) P/E Is Difficult Right NowWhen close to half the companies in France have price-to-earnings ratios (or "P/E's") below 15x, you may consider...
お知らせ • Jan 11+ 1 more updateIntegraGen SA to Report Fiscal Year 2022 Results on Apr 24, 2023IntegraGen SA announced that they will report fiscal year 2022 results on Apr 24, 2023
Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.43, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 12x in the Biotechs industry in France. Total returns to shareholders of 33% over the past three years.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 20First half 2022 earnings releasedFirst half 2022 results: Revenue: €6.76m (up 34% from 1H 2021). Net loss: €141.0k (loss narrowed 66% from 1H 2021).
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 10First half 2021 earnings releasedThe company reported a soft first half result with weaker earnings and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €5.14m (up 9.2% from 1H 2020). Net loss: €411.0k (down €427.6k from profit in 1H 2020).
Breakeven Date Change • Jun 20Forecast to breakeven in 2021The analyst covering IntegraGen expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2021. Earnings growth of 122% is required to achieve expected profit on schedule.
Reported Earnings • Apr 26Full year 2020 earnings releasedThe company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €9.15m (up 11% from FY 2019). Net loss: €375.0k (loss widened 32% from FY 2019).
Is New 90 Day High Low • Nov 16New 90-day low: €2.12The company is down 3.0% from its price of €2.18 on 18 August 2020. The French market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period.
Is New 90 Day High Low • Oct 24New 90-day high: €2.30The company is up 5.0% from its price of €2.20 on 24 July 2020. The French market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 13% over the same period.
お知らせ • Sep 17OncoDNA SA signed an agreement to acquire IntegraGen SA (ENXTPA:ALINT) for €14.5 million.OncoDNA SA signed an agreement to acquire IntegraGen SA (ENXTPA:ALINT) for €14.5 million on July 8, 2020. OncoDNA will acquire all shares of IntegraGen at an offer per share of €2.20. The transaction is structured as a tender offer. The transaction is subject to the approval of the Autorité des Marchés Financiers and applicable regulations to foreign investment control in France. The offer was approved on a unanimous basis by all members of the Board of both companies. As of September 15, 2020, the transaction was approved by AMF. The offer shall be opened at the end of the third quarter of 2020. On September 16, 2020, Oncodna formally launched the tender offer and will be open for acceptances in the next 25 days. ODDO BHF SCA acted as financial advisor, White & Case LLP Avocats-Advocaten and Osborne Clarke BV CVBA acted as legal advisors for OncoDNA. Portzamparc acted as financial advisor, Olivier Grivillers of Crowe HAF acted as fairness opinion provider and Jones Day acted as legal advisor for IntegraGen.